SCHEMBL5544589

SCHEMBL5544589

[CH2]c1ccccc1NCc1ccc(OC(C)C)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
MEN1 O00255 6/20 0.46
KMT2A Q03164 6/20 0.46
MITF O75030 1/20 0.46
LMNA P02545 3/20 0.44
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.42
MAPK1 P28482 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
F2 P00734 1/20 0.42
PRSS1 P07477 1/20 0.42
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41
POLB P06746 1/20 0.41
ALPL P05186 1/20 0.40
ALPI P09923 1/20 0.40
ALPG P10696 1/20 0.40
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5544468 0.83 HIF1A (0.51) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL5537509 0.80 NPC1 (0.50) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL19223057 0.79 PPARG (0.60) KDM4CNPC1RAB9AMEN1KMT2A
SCHEMBL5542578 0.77 HTT (0.52) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL5538885 0.76 HSD17B10 (0.59) MEN1KMT2AALDH1A1POLBTDP1
SCHEMBL5546609 0.76 L3MBTL1 (0.47) MEN1KMT2AALDH1A1GAANPSR1
SCHEMBL5536417 0.76 KDM1A (0.46) RAB9AMEN1KMT2APPARAMAPT
SCHEMBL5539503 0.74 MAPT (0.55) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL5534733 0.74 KCNH3 (0.45) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL5544675 0.74 MAPT (0.44) NPC1RAB9AMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KDM4C 4636/4885NPC1 2404/4885RAB9A 2824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.